title: Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats.
abstract: We compared the dietary effects of dihomo-gamma-linolenic acid (DGLA) contained in the DGLA oil produced by a fungus with gamma-linolenic acid (GLA) on the fatty acid composition. Wistar rats were fed with three kinds of oil for two weeks as follows: (i) control group: corn oil; (ii) GLA group: borage oil; (iii) DGLA group: DGLA oil/safflower oil = 55:45. The DGLA concentrations in the liver, serum, and brain of the DGLA group were higher than those of the GLA oil group. We also examined the dose effect of DGLA. The DGLA levels in the liver, serum, and brain significantly increased with increasing dosage of DGLA in the diet. DGLA administration significantly increased the ratio of PGE1/PGE2 in the rat plasma. The mechanism for GLA administration to improve atopic eczema is thought to involve an increase in the concentration of DGLA metabolized from GLA, so these results suggest that the dietary effect of DGLA would be more dominant than GLA.
authors.affiliation: Department of Nutrition and Food Science, Ochanomizu University, Tokyo, Japan.
authors.forename: Rumi
authors.initials: R
authors.lastname: Umeda-Sawada
authors.forename: Yoko
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Ikuko
authors.initials: I
authors.lastname: Ushiyama
authors.forename: Satoe
authors.initials: S
authors.lastname: Sagawa
authors.forename: Yasujiro
authors.initials: Y
authors.lastname: Morimitsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawashima
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Ono
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kiso
authors.forename: Akiyo
authors.initials: A
authors.lastname: Matsumoto
authors.forename: Yousuke
authors.initials: Y
authors.lastname: Seyama
mesh_terms: D015126:8,11,14-Eicosatrienoic Acid / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000527:Alprostadil / Q000097:blood; D000818:Animals; D001921:Brain / Q000378:metabolism*; D000090943:Delta-5 Fatty Acid Desaturase; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D015232:Dinoprostone / Q000097:blood; D044943:Fatty Acid Desaturases / Q000096:biosynthesis / Q000235:genetics; D050602:Linoleoyl-CoA Desaturase / Q000096:biosynthesis / Q000235:genetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D047493:PPAR alpha / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051779:Sterol Regulatory Element Binding Proteins / Q000096:biosynthesis / Q000235:genetics; D017965:gamma-Linolenic Acid / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000090943:Delta-5 Fatty Acid Desaturase; D047493:PPAR alpha; D012333:RNA, Messenger; D051779:Sterol Regulatory Element Binding Proteins; D017965:gamma-Linolenic Acid; D044943:Fatty Acid Desaturases; D050602:Linoleoyl-CoA Desaturase; D000527:Alprostadil; D015126:8,11,14-Eicosatrienoic Acid; D015232:Dinoprostone